Brought to you by 
Watson gets rights to Synthon's biosimilar; adds to its Amgen alliance
02 Sep 2022
Executive Summary
Watson Pharmaceuticals Inc. has licensed exclusive rights to Synthon BV’s (focused on generics for cancer and immune disorders) trastuzumab, being developed as a biosimilar to Roche/Genentech Inc.’s breast and gastric cancer drug Herceptin.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Watson gets rights to Synthon's biosimilar; adds to its Amgen alliance
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice